跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NCT05330624
NCT05330624Unknown2 期

Immunogenicity and Safety of Subunit Vaccine of Plague Vaccine (F1+ rV) With Two Immunization Regimens: A Random Phase 2b Clinical Trial

Jiangsu Province Centers for Disease Control and Prevention1 个研究点 分布在 1 个国家目标入组 720 人开始时间: 2020年5月8日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
2 期
入组人数
720
试验地点
1
主要终点
the GMT of antibodies to rV antigen on Month 7 post-dose 1
研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

Plague is a potentially fatal infection in humans caused by the bacterium Yersinia pestis. Pneumonic plague is typically diagnosed in humans with high mortality. It has a long history for plague as an agent of biowarfare, and pose a serious threat to international security. Althought the killed whole-cell plague vaccine and live attenuated vaccine has been licensed. They are rarely used today because of toxicities, limited evidence for efficacy to prevent plague, and limited commercial availability. In the last twenty years, it have focused on recombinant subunit vaccines which were formed F1 and V antigens as the main composition provide greater protection than vaccines comprised of either subunit alone. This study was aim to exploring the safety and immunogenicity of a new type plague subunit vaccine which comprised natural F1 antigen and recombined V antigen (F1+rV) in two immunization regimens.

详细描述

Plague is a potentially fatal infection in humans caused by the bacterium Yersinia pestis, transmitted naturally from rodent reservoirs to humans via fleas. Human disease may also result from contact with blood or tissues of infected animals or exposure to aerosolized droplets containing bacteria. Pneumonic plague is typically diagnosed in humans with with high mortality. It has a long history for plague as an agent of biowarfare, and pose a serious threat to international security. In human history, there were three outbreaks of plague all over the world, about 200 million people died from the disease. The increasing trend of plague epidemic in recent years, some regions and countries in the world still has the outbreak of the plague. It implied that safety and safe and effective vaccine is urgently to developing.

Althought the killed whole-cell plague vaccine and live attenuated vaccine has been licensed, these vaccines cause significant adverse reactions, including fever, headache, malaise, lymphadenopathy, erythema and induration at the injection site with high degree of immune variability. They are rarely used today because of toxicities, limited evidence for efficacy to prevent plague, and limited commercial availability. Based on the researches in the last twenty years, it have focused on recombinant subunit vaccines which were formed F1 and V antigens as the main composition provide greater protection than vaccines comprised of either subunit alone. In the primary phase 2a clinical trial, 30μg formulation showed a stronger and sustained immune response. This study was aim to exploring the safety and immunogenicity of a new type plague subunit vaccine which comprised 30μg natural F1 antigen and 30μg recombined V antigen (F1+rV) in two immunization regimens.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 55 Years（Adult）
性别
All
接受健康志愿者
是

入选标准

  • •Healthy adults aged 18-55months old as established by medical history and clinical examination.
  • •The subjects' guardians are able to understand and sign the informed consent.
  • •Subjects who can and will comply with the requirements of the protocol.
  • •Subjects with temperature ≤37.0°C on axillary setting.

排除标准

  • •Family history of seizures or progressive neurological disease.
  • •Subject who has a medical history of plague, or had been vaccination of plague vaccine.
  • •Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine.
  • •Any confirmed or suspected autoimmune diseases or immune deficiency disorders, including human immunodeficiency virus (HIV) infection.
  • •Dysgenopathy or severe chronic disease.
  • •Pregnant or lactating women, women of reproductive age without contraception.
  • •Thrombocytopenia or other blood coagulation disorder, taboos of intramuscular injection and collection of blood.
  • •Difficulty in blood collection.
  • •Any prior administration of immunodepressant or corticosteroids, and antianaphylactic treatment, cytotoxic therapy in last 6 months.
  • •Any prior administration of blood products in last 3 month.
  • •Any prior administration of other research medicines in last 4 weeks.
  • •Any prior administration of attenuated live vaccine in last 4 weeks.
  • •Any prior administration of subunit or inactivated vaccines in last 2 weeks.
  • •Had fever before vaccination, subjects with temperature >37.0°C on axillary setting.
  • •Any condition that in the opinion of the investigator, may interferes the evaluation of study objectives.
  • •Exclusion Criteria for the other doses:
  • •Subject who must be excluded according to the exclusion criteria for the first dose
  • •Grade 3 or above systemic adverse reactions or unacceptable adverse reactions at injection site after the previous inoculation.
  • •Other reasons in the opinion of the investigator that affect continuing vaccination.
  • •Criteria for postponding of vaccination
  • •Recovered subject who be sick during the time window of vaccination whether to continue vaccination determined by the investigator according to the requirements of the protocol.

结局指标

主要结局

the GMT of antibodies to rV antigen on Month 7 post-dose 1

时间窗: Month 7 post-dose 1

the GMT of antibodies to rV antigen on Month 7 post-dose 1

the GMT of antibodies to F1 antigen on Month 7 post-dose 1

时间窗: Month 7 post-dose 1

the GMT of antibodies to F1 antigen on Month 7 post-dose 1

次要结局

  • The seroconversion of antibodies to F1 antigen on Month 12 post-dose 1(Month 12 post-dose 1)
  • The GMFI of antibodies to rV antigen on Month 1 post-dose 1(Month 1 post-dose 1)
  • The seroconversion of antibodies to F1 antigen on Month 3 post-dose 1(Month 3 post-dose 1)
  • The seroconversion of antibodies to F1 antigen on Month 6 post-dose 1(Month 6 post-dose 1)
  • The seroconversion of antibodies to F1 antigen on Month 7 post-dose 1(Month 7 post-dose 1)
  • The GMFI of antibodies to F1 antigen on Month 7 post-dose 1(Month 7 post-dose 1)
  • The seroconversion of antibodies to rV antigen on Month1 post-dose 1(Month 1 post-dose 1)
  • The GMFI of antibodies to F1 antigen on Month 2 post-dose 1(Month 2 post-dose 1)
  • The seroconversion of antibodies to rV antigen on Month 3 post-dose 1(Month 3 post-dose 1)
  • The GMFI of antibodies to rV antigen on Month 3 post-dose 1(Month 3 post-dose 1)
  • The GMT of antibodies to rV antigen on Month 6 post-dose 1(Month 6 post-dose 1)
  • The seroconversion of antibodies to rV antigen on Month 6 post-dose 1(Month 6 post-dose 1)
  • The GMT of antibodies to F1 antigen on Month 9 post-dose 1(Month 9 post-dose 1)
  • The GMFI of antibodies to rV antigen on Month 7 post-dose 1(Month 7 post-dose 1)
  • The GMFI of antibodies to F1 antigen on Month 1 post-dose 1(Month 1 post-dose 1)
  • The GMT of antibodies to F1 antigen on Month 2 post-dose 1(Month 2 post-dose 1)
  • The seroconversion of antibodies to rV antigen on Month 2 post-dose 1(Month 2 post-dose 1)
  • The GMT of antibodies to rV antigen on Month 3 post-dose 1(Month 3 post-dose 1)
  • The GMT of antibodies to F1 antigen on Month 3 post-dose 1(Month 3 post-dose 1)
  • The GMFI of antibodies to F1 antigen on Month 3 post-dose 1(Month 3 post-dose 1)
  • The GMT of antibodies to F1 antigen on Month 6 post-dose 1(Month 6 post-dose 1)
  • The GMFI of antibodies to F1 antigen on Month 12 post-dose 1(Month 12 post-dose 1)
  • The GMFI of antibodies to rV antigen on Month 18 post-dose 1(Month 18 post-dose 1)
  • The GMT of antibodies to rV antigen on Month24 post-dose 1(Month 24 post-dose 1)
  • The seroconversion of antibodies to rV antigen on Month 7 post-dose 1(Month 7 post-dose 1)
  • The GMT of antibodies to F1 antigen on Month 1 post-dose 1(Month 1 post-dose 1)
  • The GMT of antibodies to rV antigen on Month 1 post-dose 1(Month 1 post-dose 1)
  • The seroconversion of antibodies to F1 antigen on Month1 post-dose 1(Month 1 post-dose 1)
  • The GMT of antibodies to rV antigen on Month 2 post-dose 1(Month 2 post-dose 1)
  • The seroconversion of antibodies to F1 antigen on Month 2 post-dose 1(Month 2 post-dose 1)
  • The GMFI of antibodies to rV antigen on Month 2 post-dose 1(Month 2 post-dose 1)
  • The GMFI of antibodies to F1 antigen on Month 6 post-dose 1(Month 6 post-dose 1)
  • The GMFI of antibodies to rV antigen on Month 6 post-dose 1(Month 6 post-dose 1)
  • The GMT of antibodies to rV antigen on Month 9 post-dose 1(Month 9 post-dose 1)
  • The seroconversion of antibodies to F1 antigen on Month 9 post-dose 1(Month 9 post-dose 1)
  • The seroconversion of antibodies to rV antigen on Month 9 post-dose 1(Month 9 post-dose 1)
  • The GMFI of antibodies to F1 antigen on Month 9 post-dose 1(Month 9 post-dose 1)
  • The GMFI of antibodies to rV antigen on Month 9 post-dose 1(Month 9 post-dose 1)
  • The seroconversion of antibodies to rV antigen on Month 12 post-dose 1(Month 12 post-dose 1)
  • The GMT of antibodies to F1 antigen on Month12 post-dose 1(Month 12 post-dose 1)
  • The GMT of antibodies to rV antigen on Month12 post-dose 1(Month 12 post-dose 1)
  • The seroconversion of antibodies to F1 antigen on Month 18 post-dose 1(Month 18 post-dose 1)
  • The GMFI of antibodies to F1 antigen on Month 18 post-dose 1(Month 18 post-dose 1)
  • Proportion of subjects reporting adverse events(Day 30 post-each dose)
  • The seroconversion of antibodies to rV antigen on Month 24 post-dose 1(Month 24 post-dose 1)
  • The GMT of antibodies to rV antigen on Month18 post-dose 1(Month 18 post-dose 1)
  • The seroconversion of antibodies to rV antigen on Month 18 post-dose 1(Month 18 post-dose 1)
  • The GMT of antibodies to F1 antigen on Month24 post-dose 1(Month 24 post-dose 1)
  • The GMFI of antibodies to rV antigen on Month 12 post-dose 1(Month 12 post-dose 1)
  • The GMT of antibodies to F1 antigen on Month18 post-dose 1(Month 18 post-dose 1)
  • The seroconversion of antibodies to F1 antigen on Month 24 post-dose 1(Month 24 post-dose 1)
  • The GMFI of antibodies to rV antigen on Month 24 post-dose 1(Month 24 post-dose 1)
  • The GMFI of antibodies to F1 antigen on Month 24 post-dose 1(Month 24 post-dose 1)
  • Proportion of subjects with serious adverse events (SAE)occurring throughout the trial(Day 0 up to month 12 post dose 1)

研究者

申办方类型
Network
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

已完成
2 期
Immunogenicity and Safety of Subunit Plague VaccinePlague
NCT02596308Jiangsu Province Centers for Disease Control and Prevention240
已完成
1 期
Dose Escalation Trial of a Plague Vaccine, Flagellin/F1/V, in Healthy Adult VolunteersPlague
NCT01381744National Institute of Allergy and Infectious Diseases (NIAID)48
Unknown
不适用
Yersinia Pestis Lateral Flow Immunoassay for Blood SamplesPlague, BubonicPlague, PneumonicYersinia Pestis PlagueYersinia SepsisPlagueYersinia Pestis InfectionPneumonic PlagueYersinia Pestis BuboYersinia Pestis BuboPlague, Skin BubonicYersinia Pestis Pneumonia
NCT04688996Brimrose Technology Corporation500
已完成
4 期
Human Immune Responses to Yellow Fever VaccinationYellow Fever
NCT00694655Emory University239
招募中
不适用
Effectiveness and safety of yellow fever vaccination in patients with rheumatic diseasesC20.111VaccinationYellow Fever VaccineYellow Fever VirusAutoimmune Disease.E02.095.465.425.400.530.890D20.215.894.899.970B04.820.250.350.990
RBR-3875ddHospital Universitário Cassiano Antônio de Moraes